Business
Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 49th Annual Midwinter Meeting
MONTPELLIER, France, February 06, 2026--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 49th Annual Midwinter Meeting, taking place on February 7-11, 2026, in San Juan, Puerto Rico.
About this update from Sensorion Sas
[{"type":"text","content":"MONTPELLIER, France, February 06, 2026--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent loss disorders, today announces its participation in the Association for Research in Otolaryngology (ARO) 49th Annual Midwinter Meeting, taking place on February 7-11, 2026, in San Juan, Puerto Rico.","length":368,"tagName":"p"},{"type":"text","content":"Arnaud Giese, Ph.D., Group Leader for Animal Pharmacology Platform at Sensorion, will present the following presentation at the ARO meeting:","length":140,"tagName":"p"},{"type":"text","content":"Presentation type: Podium PresentationTitle: SENS-601, a Novel Adeno Associated Vector-Based Gene Therapy as a Treatment for the Autosomal Recessive Non-Syndromic Deafness 1A (DFNB1A)Date: Sunday, February 8, 2026Time: 11:30am ETRoom: 209ABC, Podium 6: OTOF Gene Therapy Trial Updates and New Targets: GJB2 & STRC","length":321,"tagName":"p"},{"type":"text","content":"About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve the diagnosis of these underserved illnesses. Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing lo...